Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, ...

Abbott Laboratories (NYSE:ABT) is included among the 12 Most Profitable Dividend Stocks to Buy in 2026. On January 23, ...

Abbott Labs stock drops on sales miss and weak guidance for 2026, analyst cuts price target but maintains rating.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks ...

Abbott Laboratories ( ABT) shares snapped six straight sessions of losses, as the stock closed 1.2% higher at $108.77 on Monday. The MedTech giant started its downward trend on Jan. 15. The stock has ...

Abbott stock fell more than 7% in premarket trading after the company missed on Q4 revenue and gave a weaker Q1 2026 outlook, ...

Abbott shares sank 8% as Q4 revenue of $11.5B missed the $11.8B target, with nutrition sales dropping 8.9% on price ...

Abbott Laboratories (NYSE:ABT) has greatly exceeded the broader S&P 500 index this year, with its stock price increasing by 18% compared to the S&P 500’s 6% rise. This strong performance is due to the ...